Highlights

Technology Development Fund selects six Boston Children’s technologies in 2012

Nucleosome

Boston Children’s Hospital’s Technology Development Fund (TDF) is proud to announce the selection of six projects for funding in its fourth funding cycle. In 2012, TDF received approximately 50 applications spanning multiple healthcare sectors, including pharmaceutical, medical device, diagnostic and healthcare IT. Twelve of these applications were presented to the TDF advisory board of industry thought leaders in June. The board recommended six technologies for investment by the hospital.









2012 Projects:

  • Bioenhanced repair of ACL injuries for skeletally immature patient
    Martha Murray, MD, Orthopedic Center
  • Development of a multiple antigen presentation system (MAPS) vaccine platform
    Richard Malley, MD, Division of Infectious Diseases
  • Contact lens drug delivery platform
    Daniel Kohane, MD, PhD, Department of Anesthesiology
  • Inhibiting sepiapterin reductase for treating pain and inflammation
    Clifford Woolf, MB, BCh, PhD, F.M. Kirby Neurobiology Center and Program in Neurobiology
  • Drug screening of an acetyl transferase as a novel drug target in neuroblastoma
    John Powers, PhD, Department of Hematology/Oncology
  • Communicating audiological results: A new and improved software tool
    Brian Fligor, ScD, Department of Otolaryngology and Communication Enhancement

Investigators from the selected projects will be paired with mentors from the advisory board, and will work with Monique Yoakim-Turk, PhD, partner, TDF and associate director of TIDO, and Meridith Unger, principal, TDF, to guide each project. Dr. Yoakim-Turk and Ms. Unger select Contract Research Organizations (CROs), and negotiate and execute the necessary agreements before the initiation of each project.

“With a combination of TDF resources and our network of industry advisors, the goal is to successfully advance these projects to their next inflection point, making them attractive licensing and investment opportunities for industry and venture capitalists for further product development to benefit patients outside the walls of Boston Children’s,” said Dr. Yoakim-Turk.

In addition to funding the new projects, the TDF had several exciting developments in 2012, including IND approval of a prolonged-duration local anesthetic, and two completed projects that were licensed to NewCos: the Pediatric Vision Scanner to REBIScan, and MedWatcher and HealthMap to Epidemico. Two more projects are in active discussions with industry partners.

Since the inception of the fund, Boston Children’s has invested $4.25M in 39 technologies over the first three years. These investments have led to approximately $6.8M of follow-on funding from government, foundation and philanthropic organizations.

Children's HospitalTerms and Conditions
Site Designed and Developed by Genuine